All In Biotech

Drug Trial Radar · NCT01119742

Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis

A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams to Lotrimin Ultra® Cream in Patients With Interdigital Tinea Pedis

Last checked: Nov 19, 2026Latest source record: May 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 428 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

428

Actual

Start

Jul 2010

Primary completion

Mar 2011

Study completion Jul 2011

Sponsor

Sponsor type
Industry
First posted
May 10, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate comparable safety and efficacy of Taro Pharmaceuticals, Inc butenafine hydrochloride cream 1% test product and Lotrimin Ultra cream (reference listed drug) in the treatment of interdigital tinea pedis, and to show the superiority of the active treatments over that of the placebo (vehicle).

Conditions

  • Interdigital Tinea Pedis

Interventions

  • Butenafine Hydrochloride 1%Drug

    Twice daily application for 7 days

  • Butenafine Hydrochloride 1% BDrug

    Twice daily application for 7 days

  • Butenafine Hydrochloride 1%Drug

    Twice daily application for 7 days

  • Vehicle ADrug

    Twice daily application for 7 days

  • Vehicle BDrug

    Twice daily application for 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Therapeutic CureTime frame: 42 Days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.